ERBB2 and neoplasm: The subgroup analysis by tumor staging uncovered that in the population of non-metastatic TNBC, the HER2-low group demonstrated a remarkably enhanced OS relative to the HER2-zero group, and this result was statistically significant (HR = 0.93, 95%CI: 0.90-0.97, P < 0.001).